How long does it take to take Osimertinib before resistance develops?

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI), mainly used to treat epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Due to its potent targeting of the T790M resistance mutation, osimertinib has become a first- or second-line treatment option for many patients. However, like most targeted drugs, patients may develop resistance problems after using them for a period of time, which poses challenges to treatment efficacy and long-term survival.

Clinical studies and real-world data show that most patients experience a longer period of disease control after taking osimertinib, but resistance usually emerges gradually around 18 to 24 months. The specific time varies from person to person and is related to factors such as patient differences, tumor burden, mutation type, and concomitant medications. Some patients may develop drug resistance within a year, while others remain effective after more than two years of use. The emergence of drug resistance means that the inhibitory effect of osimertinib on tumors is weakened and the tumors may progress again.

The resistance mechanism of Osimertinib is complex, including new mutations of EGFR itself (such as C797S mutation), and may also involve the activation of bypass pathways (such as MET amplification, HER2 amplification, PIK3CA mutation, etc.), and even some patients have small cell lung cancer (SCLC) transformation. These mechanisms suggest that tumors are highly heterogeneous and adaptable. Therefore, disease changes should be closely monitored during treatment, and genes should be re-tested when drug resistance occurs to formulate next treatment strategies.

For patients who develop drug resistance, treatment strategies may include replacing or combining other targeted drugs, chemotherapy, immunotherapy, or participation in clinical trials. There are also current studies exploring combination therapy of osimertinib with MET inhibitors and other drugs to overcome specific resistance mechanisms. In short, although osimertinib is currently a very important therapeutic drug for EGFR mutated lung cancer, its resistance problem is still inevitable. Regular evaluation of efficacy and molecular testing are key to achieving long-term control and extending survival.

Reference materials:https://go.drugbank.com/drugs/DB09330